Literature DB >> 22592630

Intestinal pH and gastrointestinal transit profiles in cystic fibrosis patients measured by wireless motility capsule.

Daniel Gelfond1, Changxing Ma, Jack Semler, Drucy Borowitz.   

Abstract

BACKGROUND AND AIMS: The effect of the cystic fibrosis transmembrane conductance regulator protein (CFTR) defect in pancreatic insufficient (PI) patients with cystic fibrosis (CF) on the gastrointestinal pH profile is poorly defined. Adequate and efficient neutralization of the gastric acidity in the duodenum is important for nutrient absorption and timely release of pancreatic enzyme replacement therapy (PERT). We utilized a wireless motility capsule (WMC) to study intestinal pH profile and gastrointestinal transit profile in CF subjects.
METHODS: WMC studies were done on ten adult CF patients with PI while off acid suppression medication and ten age, gender and BMI matched healthy controls. Mean pH over 1 min increments and area under the pH curve over 5 min increments was calculated for the first hour post gastric emptying. Paired t-test was used to compare means of the pH recordings, transit profiles and analysis of time interval required to reach and maintain pH >5.5 and 6.0.
RESULTS: A statistically significant difference was observed between mean pH values during the first 23 min of small bowel transit (p < 0.05). In CF subjects, there was a significant delay in time interval required to reach and sustain pH 5.5 and pH 6.0 (p < 0.001), which is required for PERT dissolution. Only small bowel transit in CF subjects was noted to be significantly delayed (p = 0.004) without a compensatory increase in whole gut transit time.
CONCLUSIONS: We have demonstrated a significant delay in the small intestinal transit and a deficient buffering capacity required to neutralize gastric acid in the proximal small bowel of patients with CF.

Entities:  

Mesh:

Year:  2012        PMID: 22592630     DOI: 10.1007/s10620-012-2209-1

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  22 in total

Review 1.  Gastroduodenal mucus bicarbonate barrier: protection against acid and pepsin.

Authors:  Adrian Allen; Gunnar Flemström
Journal:  Am J Physiol Cell Physiol       Date:  2005-01       Impact factor: 4.249

2.  Dual role of CFTR in cAMP-stimulated HCO3- secretion across murine duodenum.

Authors:  L L Clarke; M C Harline
Journal:  Am J Physiol       Date:  1998-04

3.  Critical examination of therapeutic efficacy of a pH-sensitive enteric-coated pancreatic enzyme preparation in treatment of exocrine pancreatic insufficiency secondary to cystic fibrosis.

Authors:  S K Dutta; V S Hubbard; M Appler
Journal:  Dig Dis Sci       Date:  1988-10       Impact factor: 3.199

4.  The area under pH curve: a single-figure parameter representative of esophageal acid exposure.

Authors:  J A Tovar; M A Izquierdo; I Eizaguirre
Journal:  J Pediatr Surg       Date:  1991-02       Impact factor: 2.545

5.  Intestinal bicarbonate secretion in cystic fibrosis mice.

Authors:  L L Clarke; X Stien; N M Walker
Journal:  JOP       Date:  2001-07

6.  Differences in intragastric pH in diabetic vs. idiopathic gastroparesis: relation to degree of gastric retention.

Authors:  William L Hasler; Radoslav Coleski; William D Chey; Kenneth L Koch; Richard W McCallum; John M Wo; Braden Kuo; Michael D Sitrin; Leonard A Katz; Judy Hwang; John R Semler; Henry P Parkman
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2008-04-10       Impact factor: 4.052

7.  Omeprazole, a proton pump inhibitor, improves residual steatorrhoea in cystic fibrosis patients treated with high dose pancreatic enzymes.

Authors:  Marijke Proesmans; Kris De Boeck
Journal:  Eur J Pediatr       Date:  2003-09-17       Impact factor: 3.183

8.  Decline of exocrine pancreatic function in cystic fibrosis patients with pancreatic sufficiency.

Authors:  R T Couper; M Corey; D J Moore; L J Fisher; G G Forstner; P R Durie
Journal:  Pediatr Res       Date:  1992-08       Impact factor: 3.756

9.  Investigation of colonic and whole-gut transit with wireless motility capsule and radiopaque markers in constipation.

Authors:  Satish S C Rao; Braden Kuo; Richard W McCallum; William D Chey; John K DiBaise; William L Hasler; Kenneth L Koch; Jeffrey M Lackner; Carrie Miller; Richard Saad; Jack R Semler; Michael D Sitrin; Gregory E Wilding; Henry P Parkman
Journal:  Clin Gastroenterol Hepatol       Date:  2009-05       Impact factor: 11.382

10.  Comparison of gastrointestinal pH in cystic fibrosis and healthy subjects.

Authors:  C A Youngberg; R R Berardi; W F Howatt; M L Hyneck; G L Amidon; J H Meyer; J B Dressman
Journal:  Dig Dis Sci       Date:  1987-05       Impact factor: 3.199

View more
  36 in total

1.  Fecal Human β-Defensin 2 in Children with Cystic Fibrosis: Is There a Diminished Intestinal Innate Immune Response?

Authors:  Chee Y Ooi; Tamara Pang; Steven T Leach; Tamarah Katz; Andrew S Day; Adam Jaffe
Journal:  Dig Dis Sci       Date:  2015-08-14       Impact factor: 3.199

Review 2.  Unmet needs in cystic fibrosis: the next steps in improving outcomes.

Authors:  Natalie E West; Patrick A Flume
Journal:  Expert Rev Respir Med       Date:  2018-06-19       Impact factor: 3.772

3.  A high prevalence of chronic gastrointestinal symptoms in adults with cystic fibrosis is detected using tools already validated in other GI disorders.

Authors:  Bu'Hussain Hayee; Kerry-Lee Watson; Sanchika Campbell; Anna Simpson; Emma Farrell; Penelope Hutchings; Patricia Macedo; Felicity Perrin; Kevin Whelan; Caroline Elston
Journal:  United European Gastroenterol J       Date:  2019-08       Impact factor: 4.623

Review 4.  The Enigmatic Gut in Cystic Fibrosis: Linking Inflammation, Dysbiosis, and the Increased Risk of Malignancy.

Authors:  Millie Garg; Chee Y Ooi
Journal:  Curr Gastroenterol Rep       Date:  2017-02

Review 5.  The Wireless Motility Capsule: a One-Stop Shop for the Evaluation of GI Motility Disorders.

Authors:  Richard J Saad
Journal:  Curr Gastroenterol Rep       Date:  2016-03

6.  Pancreatic Enzyme Replacement Therapy Use in Infants With Cystic Fibrosis Diagnosed by Newborn Screening.

Authors:  Daniel Gelfond; Sonya L Heltshe; Michelle Skalland; James E Heubi; Margaret Kloster; Daniel H Leung; Bonnie W Ramsey; Drucy Borowitz
Journal:  J Pediatr Gastroenterol Nutr       Date:  2018-04       Impact factor: 2.839

Review 7.  Stem cell-derived organoids to model gastrointestinal facets of cystic fibrosis.

Authors:  Meike Hohwieler; Lukas Perkhofer; Stefan Liebau; Thomas Seufferlein; Martin Müller; Anett Illing; Alexander Kleger
Journal:  United European Gastroenterol J       Date:  2016-09-21       Impact factor: 4.623

8.  Clinical mechanism of the cystic fibrosis transmembrane conductance regulator potentiator ivacaftor in G551D-mediated cystic fibrosis.

Authors:  Steven M Rowe; Sonya L Heltshe; Tanja Gonska; Scott H Donaldson; Drucy Borowitz; Daniel Gelfond; Scott D Sagel; Umer Khan; Nicole Mayer-Hamblett; Jill M Van Dalfsen; Elizabeth Joseloff; Bonnie W Ramsey
Journal:  Am J Respir Crit Care Med       Date:  2014-07-15       Impact factor: 21.405

9.  Cell-specific effects of luminal acid, bicarbonate, cAMP, and carbachol on transporter trafficking in the intestine.

Authors:  Robert L Jakab; Anne M Collaco; Nadia A Ameen
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2012-08-30       Impact factor: 4.052

10.  Nutritional Status Improved in Cystic Fibrosis Patients with the G551D Mutation After Treatment with Ivacaftor.

Authors:  Drucy Borowitz; Barry Lubarsky; Michael Wilschanski; Anne Munck; Daniel Gelfond; Frank Bodewes; Sarah Jane Schwarzenberg
Journal:  Dig Dis Sci       Date:  2015-08-07       Impact factor: 3.199

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.